Likewise, no increase of pancreatitis or pancreatic carcinoma was detected in recent large-scale, placebo-controlled, double-blind trials of DPP-4 inhibitors, including SAVOR-TIMI 53 and EXAMINE. Here, DPP4 is linked to pancreatitis.